AssetMark Inc’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $13.9M | Buy |
37,935
+5,536
| +17% | +$1.89M | 0.02% | 488 |
|
|
2026
Q2 | $9.23M | Buy |
32,399
+2,830
| +10% | +$834K | 0.02% | 579 |
|
|
2026
Q1 | $8.78M | Buy |
29,569
+4,755
| +19% | +$1.54M | 0.02% | 535 |
|
|
2025
Q4 | $7.54M | Buy |
24,814
+1,833
| +8% | +$600K | 0.02% | 559 |
|
|
2025
Q3 | $7.83M | Buy |
22,981
+1,834
| +9% | +$557K | 0.02% | 526 |
|
|
2025
Q2 | $5.12M | Buy |
21,147
+1,371
| +7% | +$336K | 0.01% | 575 |
|
|
2025
Q1 | $5.38M | Buy |
19,776
+1,235
| +7% | +$289K | 0.01% | 495 |
|
|
2024
Q4 | $3.42M | Buy |
18,541
+1,383
| +8% | +$283K | 0.01% | 589 |
|
|
2024
Q3 | $3.85M | Sell |
17,158
-1,450
| -8% | -$261K | 0.01% | 495 |
|
|
2024
Q2 | $2.65M | Buy |
18,608
+1,931
| +12% | +$298K | 0.01% | 544 |
|
|
2024
Q1 | $2.61M | Buy |
16,677
+4,781
| +40% | +$770K | 0.01% | 525 |
|
|
2023
Q4 | $2.15M | Buy |
11,896
+1,404
| +13% | +$254K | 0.01% | 522 |
|
|
2023
Q3 | $1.89M | Buy |
10,492
+961
| +10% | +$190K | 0.01% | 514 |
|
|
2023
Q2 | $1.7M | Buy |
9,531
+914
| +11% | +$210K | 0.01% | 508 |
|
|
2023
Q1 | $1.86M | Buy |
8,617
+2,768
| +47% | +$664K | 0.01% | 469 |
|
|
2022
Q4 | $1.29M | Buy |
5,849
+271
| +5% | +$49.7K | 0.01% | 521 |
|
|
2022
Q3 | $752K | Buy |
5,578
+960
| +21% | +$165K | ﹤0.01% | 581 |
|
|
2022
Q2 | $747K | Buy |
4,618
+732
| +19% | +$114K | ﹤0.01% | 567 |
|
|
2022
Q1 | $733K | Buy |
3,886
+2,238
| +136% | +$476K | ﹤0.01% | 545 |
|
|
2021
Q4 | $446K | Buy |
1,648
+1,360
| +472% | +$459K | ﹤0.01% | 561 |
|
|
2021
Q3 | $105K | Buy |
288
+58
| +25% | +$19K | ﹤0.01% | 640 |
|
|
2021
Q2 | $79K | Buy |
230
+1
| +0.4% | +$331 | ﹤0.01% | 676 |
|
|
2021
Q1 | $80K | Buy |
229
+35
| +18% | +$11.6K | ﹤0.01% | 656 |
|
|
2020
Q4 | $50K | Buy |
194
+11
| +6% | +$3.03K | ﹤0.01% | 713 |
|
|
2020
Q3 | $52K | Buy |
183
+27
| +17% | +$6.35K | ﹤0.01% | 670 |
|
|
2020
Q2 | $29K | Buy |
156
+2
| +1% | +$326 | ﹤0.01% | 746 |
|
|
2020
Q1 | $19K | Buy |
154
+3
| +2% | +$469 | ﹤0.01% | 887 |
|
|
2019
Q4 | $25K | Sell |
151
-7
| -4% | -$1.16K | ﹤0.01% | 890 |
|
|
2019
Q3 | $19K | Hold |
158
| – | – | ﹤0.01% | 894 |
|
|
2019
Q2 | $20K | Buy |
158
+1
| +0.6% | +$127 | ﹤0.01% | 885 |
|
|
2019
Q1 | $21K | Buy |
+157
| New | +$21.2K | ﹤0.01% | 877 |
|
Other funds holding ONC
AssetMark Inc's ONC Position: Q3 2026 in Review
AssetMark Inc increased its BeOne Medicines Ltd (ONC) stake by 17% in Q3 2026, buying an estimated $1.89M and bringing the position to 37,935 shares worth $13.9M. The position accounts for 0.02% of the portfolio, ranked #488.
AssetMark Inc first reported a position in ONC in Q1 2019 and has held it in 31 quarters since. 110 funds tracked by Wall St. Rank hold ONC as of Q3 2026.
- AssetMark Inc held 37,935 shares of BeOne Medicines Ltd worth $13.9M as of Q3 2026.
- AssetMark Inc bought 5,536 BeOne Medicines Ltd shares in Q3 2026, an estimated $1.89M.
- BeOne Medicines Ltd made up 0.02% of AssetMark Inc's portfolio in Q3 2026, its #488 holding.
- AssetMark Inc first reported a position in BeOne Medicines Ltd in Q1 2019 and has held it in 31 quarters since.
- 110 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2026.
Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.